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Abstract
Venous thromboembolism is a very common pathological process for which there are many well known (and less
well-known) predisposing factors. Likewise, olanzapine is a commonly used anti-psychotic medication.
We present the case of a young Somali gentleman who developed venous thromboembolic disease after an over-
dose of olanzapine. The diagnosis was only made 48 hours after admission, due to the non-specific presentation of
the pulmonary embolus and the fact that the link between olanzapine and pulmonary embolus was not previously
widely described and therefore it did not immediately figure in the differential diagnosis. The patient made a full
recovery.
There is an increasing body of circumstantial evidence linking olanzapine to pulmonary embolus. Clinicians should
bear this possible association in mind when prescribing the drug and when faced with clinical situations where
venous thromboembolism (VTE) is a possible diagnosis. VTE has occasionally been described in therapeutic dose
olanzapine therapy, but never in the context of an acute overdose. Khat, a recreational drug, has been linked to
arterial, but not venous thrombosis.
It is hoped that this case report will further encourage research into these associations, which remain to be proven
and quantified.
In the context of changing population demographics and increasing global migration, a greater awareness of the
potential effects of endemic practices and their potential consequences is essential to the modern-day doctor
working in a multi-cultural society.
Introduction
Olanzapine is an atypical anti-psychotic, very commonly
used in the management of schizophrenia and mania.
There are a number of reported side effects of this drug,
including weight-gain, sedation and anti-muscarinic
effects but until recently there was no known link to
thromboembolic disease.
Venous thromboembolism is a common pathological
process for which many risk factors have been
described. The commonest are immobility, malignancy,
surgery and hypercoagulable states. Some drugs, includ-
ing the typical anti-psychotics, have long been known to
increase the risk of venous thromboembolism, however
it was not until very recently that atypical anti-psycho-
tics and indeed olanzapine were shown to be related to
this disorder.
We describe an interesting case of massive pulmonary
embolism temporally related to ingestion of an olanzapine
overdose and explore the existing literature on the topic.
Case presentation
Case Presentation
A 27-year old, obese Somali gentleman was admitted
with a history of acute onset of hallucinations and delir-
ious behaviour. He was found by his relatives with sus-
pected olanzapine overdose and had been on the floor
f o rm o r et h a nt w od a y s .H eh a dap a s th i s t o r yo f
depression and psychosis for which he was on this med-
ication. The patient also had a longstanding history of
“Khat” abuse (a flowering plant with amphetamine-like
effects). On admission, he was noted to be disorientated
and confused. He was afebrile, tachycardic and had a
blood pressure of 110/70. His oxygen saturations were
normal. Cardiovascular, respiratory, abdominal and neu-
rological examinations were unremarkable. There were
no signs of meningism.
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Blood tests revealed no significant abnormalities apart
from elevated Creatine Kinase of 4,800 u/l, which was
presumed to be due to rhabdomyolysis secondary to
lying on the floor for a prolonged period. Arterial blood
gases and chest X-RAY were normal, whilst his ECG
showed sinus tachycardia. A CT scan of his brain did
not reveal any abnormalities. Urine dipstick showed no
evidence of a urinary tract infection. Serial ECGs
showed the development of widespread flattened T
w a v e sa n dr i g h ta x i sd e v i a t i o n .AC Tp u l m o n a r ya n g i o -
gram was performed 48 hours after admission and
revealed extensive pulmonary thrombo-embolic disease
and right lower lobe consolidation.
Differential Diagnosis
￿ Cardiac event
￿ Drug-induced arrhythmia
￿ Pulmonary embolus
￿ Lower respiratory tract infection
Treatment
He was started on intravenous antibiotics for possible
aspiration pneumonia and anticoagulation for pulmon-
ary embolism.
Outcome and Follow up
He was subsequently reviewed by the psychiatrists and
admitted to storing 90 olanzapine tablets and taking
these with a clear suicidal intent following a severe
depressive episode. He denied having taken any other
medications and no other empty packaging was found,
apart from that of his olanzapine tablets. Following
medical treatment for the pulmonary embolus and
lower respiratory tract infection, he was discharged to
the care of the mental health team. He has since recov-
ered completely.
Discussion
The link between conventional anti-psychotic medica-
tions and venous thromboembolism (VTE) was first sug-
gested in the 1950s. However, there have been few case
reports and case-control studies to support an associa-
tion between atypical anti-psychotics and VTE and
these are mainly related to clozapine. One retrospective
study of nursing home residents suggested that atypical
anti-psychotics appear to increase the risk of VTE,
though such events remain rare [1]. It also showed that,
of the atypical agents commonly used, clozapine had the
strongest links to VTE [1]. One series described three
elderly patients with possible association between
chronic use of olanzapine and VTE and there is one
case report of VTE in a young male after starting olan-
zapine therapy.
In recent months, three further reports detailing six
more cases of VTE in patients on olanzapine were
published, however in four of these cases, multiple other
clinical and biochemical risk factors for VTE were pre-
sent. A team of forensic pathologists from USA has
reported six cases of fatal pulmonary embolus occurring
over a seven year period where the patients concerned
were on olanzapine therapy, which may therefore have
been a contributing factor [2].
There have been few mechanisms postulated to
explain these associations. Clozapine, but not the other
atypical antipsychotics, has been shown to have a weak
association with in-vitro platelet adhesion, aggregation
and plasma coagulation [3]. Atypical anti-psychotics
have been associated with sedating effects, a more
sedentary lifestyle and weight gain, all of which are pre-
disposing risk factors for VTE [4]. Indeed, this patient
was obese and had been immobilised for two days prior
to hospital admission, due to sedation induced by the
overdose. He worked as a taxi driver and stated that he
did no regular exercise.
Atypical agents also possess a high affinity for the ser-
otonin receptor type 2A, and serotonin-induced platelet
aggregation may be affected [5]. Metabolic abnormalities
such as dyslipidaemia, hyperleptinaemia, hyperglycaemia
and hyperhomocysteinaemia have been observed in
users of atypical antipsychotics [4] and all are associated
with decreased fibrinolytic activity. However, these are
unlikely to be aetiologic factors in early thromboembolic
occurrence [1].
Recent small and preliminary studies have yielded
conflicting results, with one retrospective study of the
WHO database for adverse drug reactions noting that
pulmonary embolism occurred with a higher frequency
in patients on olanzapine than on other drugs, though
conceding that these conclusions were based on incom-
plete data [6]. Another study in 2008 concluded that
olanzapine did not have any direct effect on pro- or
anticoagulant activity or fibrinogen levels. Although this
study showed that patients on long-term olanzapine
therapy had increased leptin and PAI-1 levels compared
to controls, they did not have significantly different
levels to those in their untreated first degree relatives.
The authors postulated that increased incidence of VTE
in these individuals may be due to obesity and lifestyle
rather than an effect on coagulation [7]. The link
between VTE and this patient subset may also be due to
other factors relating to lifestyle that are associated with
these illnesses [4].
Khat (Catha edulis Forsk, also known as qat, mirra, jaad
or qaad) is a herbal drug, widely used in East Africa and
the Arabian Peninsula for centuries. The main active
ingredient is cathinone, a sympathomimetic amine alkaloid
thought to have effects similar to amphetamines [8]
including euphoria, hyperexcitability, insomnia, paranoia
and psychosis. Peripheral effects of khat may be related to
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and an increased heart rate [9].
Potential links between Khat use and arterial throm-
bosis [9,10] (ischaemic stroke and myocardial infarct
through coronary vasospasm, catecholamine-mediated
platelet aggregation and increased myocardial oxygen
demand) have been described in the literature, but to
our knowledge none with VTE.
This gentleman’s pulmonary embolus could have
occurred at any point from ingestion of the olanzapine
tablets and during his subsequent immobilisation, until
his CTPA scan. The fact that he had a sinus tachycardia
(the commonest ECG finding in pulmonary embolus)
that did not respond to adequate fluid resuscitation
would suggest that this was not simple dehydration. He
developed dynamic ECG changes within 36 hours of
admission and his saturations dropped, probably as the
thromboembolic episode progressed.
His obesity and period of immobilisation predisposed
to VTE and therapeutic doses of olanzapine have been
linked to VTE. This case report poses the question of
olanzapine overdose, khat abuse or the combination of
both having contributed to his life-threatening throm-
boembolic episode.
Conclusion
There appears to be a possible relationship between use
of olanzapine and venous thromboembolism and further
s t u d yi n t ot h i si sn e e d e dt oc o n f i r ma n dq u a n t i f yi t .I t
remains to be seen whether this relationship is dose
dependant, as might be suggested by the presentation in
our case. Clinicians should bear this in mind when pre-
scribing this drug and when faced with clinical situa-
tions where venous thromboembolism is an obvious (or
not so obvious!) diagnosis. Although there is no evi-
dence as yet, one might also exercise caution when pre-
scribing olanzapine to patients at high risk of VTE. VTE
has occasionally been described in therapeutic dose
olanzapine therapy, but never in the context of an acute
overdose. It is hoped that this case report will further
encourage study of the relationship.
Take Home Points
￿ There is an increasing body of circumstantial evi-
dence linking olanzapine to venous thromboem-
bolism.
￿ Pulmonary embolism should be considered in the
differential diagnosis of patients presenting with
non-specific features of this condition, even if they
initially appear to have no risk factors.
￿ In the context of changing population demo-
graphics and increasing global migration, a greater
awareness of the potential effects of endemic prac-
tices is essential.
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